Zentek Granted Second Patent from the Canadian Intellectual Patent Office
Zentek has been granted a second patent by the Canadian Intellectual Property Office for its Graphene Oxide-Cationic Silver (GO-Ag+) Nanocomposites, recognized as a broad-spectrum antimicrobial agent.
The patent includes 64 successful claims and covers the compound's use against bacteria, fungi, and viruses in various forms such as liquid, powder, and ointments. Zentek has also applied for this patent with the U.S. Patent and Trademark Office.
GO-Ag+ has shown higher cytotoxicity against bacteria than human cells and is being studied for its effectiveness in preventing and eliminating biofilms, a significant challenge in wound care and medical devices. The patent supports further development of GO-Ag+-based products for medical and veterinary markets.
CEO Greg Fenton emphasized that this milestone is important for Zentek's intellectual property commercialization strategy and aims to maximize shareholder value.
- Zentek received a second patent for GO-Ag+ from the Canadian Intellectual Property Office.
- The patent includes 64 successful claims, enhancing Zentek's IP portfolio.
- GO-Ag+ is recognized as an effective antimicrobial agent against bacteria, fungi, and viruses.
- The patent covers various forms of GO-Ag+, including liquid, powder, and ointments.
- Zentek applied for the same patent with the U.S. Patent and Trademark Office.
- GO-Ag+ has demonstrated higher cytotoxicity against bacteria than human cells.
- The compound is being studied for preventing and eliminating biofilms, important for wound care and medical devices.
- The new patent supports further development of GO-Ag+-based products for medical and veterinary markets.
- No financial data provided to gauge immediate impact on revenue.
- Uncertainty regarding the U.S. patent application outcome.
- Potential delays in product development and market entry.
Insights
Zentek's second patent from the Canadian Intellectual Property Office for its GO-Ag+ nanocomposite formulation is a significant development. From a financial perspective, securing a patent provides intellectual property protection, which can lead to a monopolistic advantage in the market. This means Zentek could potentially have exclusive rights to manufacture and sell products containing GO-Ag+, thus limiting competition and potentially driving higher revenues.
Additionally, the application for a similar patent with the United States Patent and Trademark Office indicates the company's strategy to protect its innovation in larger markets, further enhancing its market growth potential. This strategy could attract more investors looking for companies with unique, protected technology, leading to increased investor confidence and potentially boosting stock prices in the short term.
However, investors should also consider the costs associated with bringing a new product to market, including R&D expenses, regulatory hurdles and marketing efforts. These costs can be substantial and may impact the company's financial performance in the near term.
The granted patent for the GO-Ag+ nanocomposite, which has shown higher cytotoxicity against gram-positive and gram-negative bacteria compared to human epithelial cells, represents an important milestone for Zentek. This points to a credible advancement in antimicrobial agents used in medical applications. The ongoing research into its efficacy against biofilms, a significant issue in wound care and medical devices, enhances its potential utility. If research continues to show promising results, the GO-Ag+ compound could be groundbreaking for wound care products and other medical applications, addressing a critical need in the healthcare industry.
This development can lead to new product lines in both human and veterinary medicine, expanding Zentek's potential market reach. For retail investors, this presents a promising opportunity, albeit with typical risks associated with medical innovations. The transition from research to commercial product involves rigorous testing and regulatory approval, which can delay market entry and require significant investment.
GUELPH, ON / ACCESSWIRE / May 27, 2024 / Zentek Ltd. ("Zentek" or the "Company") (Nasdaq:ZTEK)(TSXV:ZEN), an intellectual property technology development and commercialization company has received a second patent by the Canadian Intellectual Property Office titled: Graphene Oxide-Cationic Silver (GO-Ag+) Nanocomposites and Their Use as a Broad-Spectrum Antimicrobial Agent and includes a total of 64 successful claims. The Company also applied for this patent with the United States Patent and Trademark Office. The patent claims the novel GO-Ag+ compound, that is the active ingredient for ZenGUARD™ , as an effective agent against both regular and resistant bacteria, fungi and viruses. The patent claims liquid, powder and ointments that use GO-Ag+ as the active ingredient.
Zentek continues to do extensive work with GO-Ag+ in collaboration with the University of Guelph. In previous research, GO-Ag+ demonstrated substantially higher cytotoxicity against gram positive and negative bacteria than for human epithelial cells. In current research, the efficacy of Go-Ag+ is being studied to prevent and eliminate biofilms which is a critical challenge for wound care and various medical devices. These results, along with the new patent support future work to develop GO-Ag+ based products for medical and veterinarian markets including wound care products.
"We are very pleased to expand the use case and patent protection of the GO-Ag+ active ingredient in ZenGUARD™ and we see this as another important milestone in our IP commercialization strategy," said Greg Fenton, CEO of Zentek. "Now that we have secured a patent for our GO-Ag+ formulation as a therapeutic that could apply to both human and veterinary medicine, we will focus on how to maximize shareholder value from this opportunity while balancing the other priorities of the Company."
About Zentek Ltd.
Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the company's commercial partners a competitive advantage by making their products better, safer, and greener.
Zentek's patented technology platform ZenGUARD™, is shown to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC (heating, ventilation, and air conditioning) systems. Zentek's ZenGUARD™ production facility is located in Guelph, Ontario.
Zentek, through its wholly owned subsidiary, Triera Biosciences Ltd., has a global exclusive licence to the aptamer-based platform technology developed by McMaster University, which is being jointly developed by Zentek and McMaster for both the diagnostic and therapeutic markets.
For further information:
Investorrelations@zentek.com
Ryan Shacklock
Tel: 306-270-9610
Email: rshacklock@zentek.com
To find out more about Zentek, please visit our website at www.Zentek.com. A copy of this news release and all material documents in respect of the Company may be obtained on Zentek's SEDAR+ profile at http://www.sedarplus.ca/.
Forward-Looking Statements
This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Zentek Ltd.
View the original press release on accesswire.com
FAQ
What recent patent did Zentek receive?
What is Zentek's new patent about?
How many claims does Zentek's new patent include?
What forms does the new Zentek patent cover?
Has Zentek applied for the GO-Ag+ patent in other countries?
What is the potential application of GO-Ag+ according to Zentek?
What markets is Zentek targeting with its new patent?
